Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 95Sarcoma 5Gynecologic 5Genitourinary 5Head & Neck 4Breast 4Endocrine 3Thoracic 2Dermatologic 2CNS 2Other solid neoplasm 1NET 1Lymphoid 1

Conditions

Lymphoma 900Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Lymphoma, Follicular 516Hodgkin Disease 442Lymphoma, Mantle-Cell 421Leukemia 410Lymphoma, B-Cell, Marginal Zone 289Burkitt Lymphoma 285Recurrence 276Leukemia, Myeloid, Acute 276Multiple Myeloma 250Myelodysplastic Syndromes 237Waldenstrom Macroglobulinemia 187Lymphoma, B-Cell 178Lymphoma, Large-Cell, Immunoblastic 153Lymphoma, T-Cell, Cutaneous 143Leukemia, Myelogenous, Chronic, BCR-ABL Positive 127Lymphoma, T-Cell, Peripheral 123Mycosis Fungoides 118Myeloproliferative Disorders 112Lymphoma, Large-Cell, Anaplastic 107Dendritic Cell Sarcoma, Interdigitating 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Neoplasms 98Lymphoma, Extranodal NK-T-Cell 96Hematologic Neoplasms 96Sezary Syndrome 94

Interventions

IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × Lymphoid × Clear all
NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Sorrento Therapeutics, Inc.

Phase 2 Withdrawn
GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡